Skip to main content

Table 4 Base Case Values of Cost-Effectiveness Analysis of Three Strategies in China and the USA

From: Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Parameters China USA
TACE Full-dose Sorafenib Dose-adjusted Sorafenib TACE Full-dose Sorafenib Dose-adjusted Sorafenib
LYG (months) 6.357 7.236 7.898 6.357 7.236 7.898
QALYs (years) 0.375 0.435 0.482 0.375 0.435 0.482
Lifetime cost ($) 10,642.22 16,703.95 10,488.72 95,061.13 34,190.70 23,377.97.54
\